Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI -5.41%46 3-Year ROIIC % is 74.95 as of Jun. 2025, which is 328% above its 10-year median of 17.51. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.62 (Significantly Undervalued). Among 946 Drug Manufacturers companies, ODI Pharma AB ranks better than 87.63% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ODI Pharma AB's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 74.95%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ODI Pharma AB's 3-Year ROIIC % or its related term are showing as below:
XSAT:ODI's 3-Year ROIIC % is ranked better than 87.63% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs XSAT:ODI: 74.95
ODI Pharma AB (XSAT:ODI) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ODI Pharma AB 3-Year ROIIC % Related Terms
ODI Pharma AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's 3-Year ROIIC % falls into.
ODI Pharma AB's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -5.451 (Jun. 2025) - -7.207 (Jun. 2022) )
/
( 4.797 (Jun. 2025) - 2.454 (Jun. 2022) )
=
1.756
/
2.343
=
74.95%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ODI Pharma AB (XSAT:ODI) has a 3-Year ROIIC % of 74.95 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ODI Pharma AB and its competitors. This is 328% above median its historical median of 17.51. According to the industry distribution chart, ODI Pharma AB ranks #117 out of 946 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is ODI Pharma AB's 3-Year ROIIC % too high?
ODI Pharma AB's current 3-Year ROIIC % of 74.95 is 328% above median its 10-year median of 17.51. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. ODI Pharma AB's value of 74.95 is 1976.2% above this industry median. Based on the distribution chart, ODI Pharma AB ranks #117 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #117 out of 946 companies for 3-Year ROIIC %. This places ODI Pharma AB in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.61. ODI Pharma AB's value of 74.95 is 1976.2% above this benchmark. While the company's 10-year median is 17.51 vs. the industry median of 3.61, ODI Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current 3-Year ROIIC % of 74.95 is 1976.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current 3-Year ROIIC % is 74.95, which is 328% above median its own 10-year median of 17.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.62, compared to a current price of kr2.10 — trading 78.2% below its estimated fair value. The current 3-Year ROIIC % is 74.95, which is 328% above median its 10-year median of 17.51 and 1976.2% above the Drug Manufacturers industry median of 3.61. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current 3-Year ROIIC % is 74.95 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.10 is trading 78.2% below its estimated GF Value™ of kr9.62.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
3-Year ROIIC %: 74.95 (328% above median its 10-year median of 17.51)
GF Value™: kr9.62 vs. price of kr2.10 (78.2% below fair value)
Industry Position: 1976.2% above the Drug Manufacturers median (#117 of 946)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
